Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 92 | ETA2023 | Next issue

45th Annual Meeting of the European Thyroid Association (ETA) 2023

Poster Presentations


ea0092ps2-15-01 | Hyperthyroidism | ETA2023

A prospective, observational study on the effect of an ablative vs a conservative approach for the treatment of graves’ hyperthyroidism in patients with moderate-to-severe, active graves’ orbitopathy

Cosentino Giada , Lanzolla Giulia , Comi Simone , Menconi Francesca , Rotondo Dottore Giovanna , Novella Maglionico Maria , Posarelli Chiara , Figus Michele , Elisei Rossella , Santini Ferruccio , Marino Michele

Objectives: Optimal treatment for Graves’ hyperthyroidism (GH) in patients with moderate-to-severe, active Graves’ orbitopathy (GO) remains to be established. There is debate on whether a conservative (antithyroid drugs, ATDs) or an ablative approach (radioactive iodine, RAI, or surgery, Tx)has to be preferred. The aim of the present study was to investigate whether these different approachesresult in a different outcome of GOfollowing intravenous glucocorticoids (iv...

ea0092ps2-15-02 | Hyperthyroidism | ETA2023

Grip strength in newly diagnosed hyperthyroidism

Tosheva Gergana , Siderova Mira

Introduction: Grip strength is a valuable biomarker of an individual’s biological age. Weak grip strength is a key component of sarcopenia and frailty and is associated with subsequent poor health, disability and mortality. Skeletal muscle is one of the major target organs of thyroid hormones. Hyperthyroidism may affect skeletal muscles qualitatively and quantitatively, to the extent of developing muscle weakness and myopathy. There are few studies investigating grip stre...

ea0092ps2-15-03 | Hyperthyroidism | ETA2023

Does iodine fortification affect the risk of atrial fibrillation in incident hyperthyroidism?

Tang Moellehave Line , Knudsen Nils , Prescott Eva , Bulow Pedersen Inge , Ravn-Haren Gitte , Linneberg Allan

Objectives: Iodine fortification (IF) induces an initial increase followed by a decrease in the incidence of hyperthyroidism in the population. Also, the sex-, age-, and subtype distribution of hyperthyroid cases changes after IF. The risk of atrial fibrillation (AF) in hyperthyroid patients is influenced by these factors. Therefore, we aimed to examine how the association between incident hyperthyroidism and atrial fibrillation was affected by an IF increasing the population ...

ea0092ps2-15-04 | Hyperthyroidism | ETA2023

THY-PRO 39 questionnaire in graves` disease patients after therapy

Villagelin Danilo , Perini Nicolas , Santos Roberto , Romaldini Joao

Introduction: Graves’ disease is the leading cause of hyperthyroidism in the adult population. Antithyroid drugs (ATD) are the first choice worldwide, however, after an initial treatment course of 18-24 months, almost 40-50% will relapse. In these cases, current guidelines suggest a second course or prolonged use of ATD as an option. Recently, the study of quality of life (QOL) has obtained great importance, since the QOL in hyperthyroid patients is very affected. However...

ea0092ps2-15-05 | Hyperthyroidism | ETA2023

Resting heart rate monitoring for optimized treatment of hyperthyroidism - the pulsar-study

Baumann Carole , Teubler Aline , Betz Matthias , Maushart Claudia

Objectives: Graves’ disease (GD) is a common cause of hyperthyroidism. An increased heart rate (HR) is a hallmark of elevated thyroid hormones (TH). In a prospective observational study we monitored HR continuously with wearable fitness trackers to evaluate the correlation between HR and TH levels and the relevance of HR monitoring for clinical management of patients with GD.Methods: Seventeen outpatients with newly diagnosed or relapsed GD starting...

ea0092ps2-15-06 | Hyperthyroidism | ETA2023

Factors influencing early outcome of radioiodine treatment in patients with graves’ disease

Pirnat Edvard , Zaletel Tjaša , Rot Živa , Gaberscek Simona , Zaletel Katja

Aim: In Graves’ disease (GD) the goal of radioiodine (I-131) application is the elimination of hyperthyroidism. The reported success rate 1 year after treatment is up to 90%. The aim of this retrospective study was to assess the factors influencing the early outcome 3 months after I-131 treatment of GD patients in an iodine sufficient area.Materials and Methods: We reviewed medical records of GD patients who received I-131 therapy between January 20...

ea0092ps2-15-07 | Hyperthyroidism | ETA2023

Immunogenetics markers of graves’ disease relapse after antithyroid treatment

Zhilina Ekaterina , Drogashevskaya Natalia , Martirosian Narine , Petunina Nina

Introduction: The choice of treatment for Graves’ disease (GD) requires a comprehensive assessment of the patient’s condition and the risk of recurrence. The aim of our study was to evaluate the association of immunological and genetic markers with GD recurrence after antithyroid treatment.Methods: We conducted a case-control study. The study included 63 patients with GD who received antithyroid treatment. After at least 12 months of withdrawal...

ea0092ps2-15-08 | Hyperthyroidism | ETA2023

Extended pharmacometrics computer model utilizes heart rate to monitor thyroid function in adults with graves’ disease under carbimazole monotherapy

Steffens Britta , Koch Gilbert , Pfister Marc , Zuger Noemi , Bachmann Freya , Schropp Johannes , Johannes Betz Matthias , Szinnai Gabor

Objectives: Graves’ disease (GD) is characterized by variable disease severity at diagnosis and variable disease activity during follow-up. Antithyroid drugs (ATD) such as carbimazole (CMZ), methimazole or propylthiouracil are the first-line treatment. Current guidelines recommend a range of ATD starting dose according to GD severity, followed by dose titration until euthyroidism is reached and a maintenance dose for a specific patient is established. As thyroid hormones ...

ea0092ps2-15-09 | Hyperthyroidism | ETA2023

Long-term follow-up after antithyroid drug treatment withdrawal in patients with the first episode of graves` disease: a retrospective cohort study in spain

Meneses Diego , Sanchez Lechuga Begona , Velez Romero Maria , Sierra Poyatos Roberto , Vazquez Martinez Clotilde , Cardenas Salas Jersy

Background: Despite a high relapse rate, antithyroid drugs (ATDs) remain the first-line therapy of Graves’ disease (GD). Long-term follow-up studies of GD in Spain are scarce. Our aims were to identify clinical differences between patients who relapsed vs those who attained remission and to describe the relapse rate of GD after ATD withdrawal.Methods: We analyzed patients with the first episode of GD who were treated with ATDs during 2010 - 2020, in...